Melatonin relieves the neural oxidative burden that contributes to dementias
- PMID: 15681808
- DOI: 10.1196/annals.1332.012
Melatonin relieves the neural oxidative burden that contributes to dementias
Abstract
This report summarizes some of the many publications that document the beneficial actions of melatonin within the central nervous system. Of particular interest are the multiple functions of melatonin and its metabolites as ubiquitously acting direct free radical scavengers and indirect antioxidants. The fact that melatonin and the metabolic progeny that are formed when it scavenges toxic reactants are all effective in neutralizing destructive molecules greatly increases the efficacy of melatonin as a protection against by-products of oxygen and nitrogen that normally mutilate essential molecules. Of the large number of situations in which oxidative stress may be the cause of disease processes or debilitating conditions, the current review examines melatonin's protection within the central nervous system, particularly in experimental ischemia/reperfusion (stroke) injury, Alzheimer's disease, and parkinsonism. In each of these conditions, melatonin has been found to provide significant neural protection against both the morphophysiological damage and the biobehavioral consequences of these infirmities. The report concludes with the suggestion that melatonin, alone or in combination with other antioxidants, be considered for routine usage to potentially combat some of the neural ravages of aging.
Similar articles
-
Melatonin: reducing molecular pathology and dysfunction due to free radicals and associated reactants.Neuro Endocrinol Lett. 2002 Apr;23 Suppl 1:3-8. Neuro Endocrinol Lett. 2002. PMID: 12019343 Review.
-
Pharmacological utility of melatonin in reducing oxidative cellular and molecular damage.Pol J Pharmacol. 2004 Mar-Apr;56(2):159-70. Pol J Pharmacol. 2004. PMID: 15156066 Review.
-
Melatonin defeats neurally-derived free radicals and reduces the associated neuromorphological and neurobehavioral damage.J Physiol Pharmacol. 2007 Dec;58 Suppl 6:5-22. J Physiol Pharmacol. 2007. PMID: 18212398 Review.
-
Beneficial effects of melatonin in cardiovascular disease.Ann Med. 2010 May 6;42(4):276-85. doi: 10.3109/07853890903485748. Ann Med. 2010. PMID: 20455793 Review.
-
Melatonin oxidative stress and neurodegenerative diseases.Indian J Exp Biol. 2002 Jun;40(6):668-79. Indian J Exp Biol. 2002. PMID: 12587715 Review.
Cited by
-
Homocysteine in Neurology: A Possible Contributing Factor to Small Vessel Disease.Int J Mol Sci. 2021 Feb 19;22(4):2051. doi: 10.3390/ijms22042051. Int J Mol Sci. 2021. PMID: 33669577 Free PMC article. Review.
-
Violet and blue light blocking intraocular lenses: photoprotection versus photoreception.Br J Ophthalmol. 2006 Jun;90(6):784-92. doi: 10.1136/bjo.2005.086553. Br J Ophthalmol. 2006. PMID: 16714268 Free PMC article.
-
The Controversial Role of Homocysteine in Neurology: From Labs to Clinical Practice.Int J Mol Sci. 2019 Jan 8;20(1):231. doi: 10.3390/ijms20010231. Int J Mol Sci. 2019. PMID: 30626145 Free PMC article. Review.
-
Cellular and biochemical actions of melatonin which protect against free radicals: role in neurodegenerative disorders.Curr Neuropharmacol. 2008 Sep;6(3):203-14. doi: 10.2174/157015908785777201. Curr Neuropharmacol. 2008. PMID: 19506721 Free PMC article.
-
Mechanisms of Melatonin in Alleviating Alzheimer's Disease.Curr Neuropharmacol. 2017;15(7):1010-1031. doi: 10.2174/1570159X15666170313123454. Curr Neuropharmacol. 2017. PMID: 28294066 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical